English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/124286
COMPARTIR / IMPACTO:
Estadísticas
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:
Título

Iro/IRX transcription factors negatively regulate Dpp/TGF-β pathway activity during intestinal tumorigenesis

AutorMartorell, Òscar; Barriga, Francisco M.; Merlos-Suárez, Anna; Attolini, Camille Stephan Otto; Casanova, Jordi ; Batlle, Eduard; Sancho, Elena; Casali, Andreu
Palabras claveDpp
EGFR/Ras
TGF-β
Wnt
Fecha de publicación8-oct-2014
EditorNature Publishing Group
European Molecular Biology Organization
CitaciónEMBO Reports 15(11): 1210-1218 (2014)
Resumen© 2014 The Authors. Activating mutations in Wnt and EGFR/Ras signaling pathways are common in colorectal cancer (CRC). Remarkably, clonal coactivation of these pathways in the adult Drosophila midgut induces >tumor-like> overgrowths. Here, we show that, in these clones and in CRC cell lines, Dpp/TGF-β acts as a tumor suppressor. Moreover, we discover that the Iroquois/IRX-family-protein Mirror downregulates the transcription of core components of the Dpp pathway, reducing its tumor suppressor activity. We also show that this genetic interaction is conserved in human CRC cells, where the Iro/IRX proteins IRX3 and IRX5 diminish the response to TGF-β. IRX3 and IRX5 are upregulated in human adenomas, and their levels correlate inversely with the gene expression signature of response to TGF-β. In addition, Irx5 expression confers a growth advantage in the presence of TGF-β, but is selected against in its absence. Together, our results identify a set of Iro/IRX proteins as conserved negative regulators of Dpp/TGF-β activity. We propose that during the characteristic adenoma-to-carcinoma transition of human CRC, the activity of IRX proteins could reduce the sensitivity to the cytostatic effect of TGF-β, conferring a growth advantage to tumor cells prior to the acquisition of mutations in TGF-β pathway components.
Versión del editorhttp://dx.doi.org710.15252/embr.201438622
URIhttp://hdl.handle.net/10261/124286
DOI10.15252/embr.201438622
Identificadoresdoi: 10.15252/embr.201438622
issn: 1469-3178
Aparece en las colecciones: (IBMB) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
accesoRestringido.pdf15,38 kBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 

Artículos relacionados:


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.